Switching from Wegovy to semaglutide: what you need to know

Wegovy, Ozempic and Rybelsus all contain semaglutide, so what's different between them?

Semaglutide is the generic molecule. The brand you receive depends on which condition it's been licensed to treat and at what dose. Wegovy (the weekly injection) is the only semaglutide product currently licensed in the UK for weight management via subcutaneous injection, starting at 0.25 mg and titrated by your prescriber up to the maintenance dose. A higher 7.2 mg weekly dose has also received MHRA approval (for adults with a BMI of 30 or above) following the MHRA's announcement in April 2026.

Ozempic is also semaglutide by injection, but at different doses and licensed only for type 2 diabetes, not for weight loss. Using it off-label for weight management is outside its licence and not something a responsible prescriber should arrange without specific clinical justification. If you're already taking Ozempic and wondering whether moving across makes sense, our page on switching from Ozempic to Wegovy walks through how that process works and what to consider. Our page comparing Wegovy and Ozempic covers this distinction fully.

Rybelsus is oral semaglutide in 3 mg, 7 mg and 14 mg tablets, again, licensed for type 2 diabetes only. Rybelsus is not the same product as the Wegovy tablet (see below). If someone has suggested switching you to Rybelsus for weight loss, that conversation needs to happen with your prescriber, because the licence doesn't cover it.

The short version: if you want to switch from Wegovy to semaglutide, you're already there. If what you actually want is to switch formulation, dose, or brand for another reason (cost, availability, tolerability, or a new clinical option) that's a different question, and a more useful one.

Is there now an oral semaglutide option for weight loss in the UK?

Yes. On 11 June 2026 the MHRA approved Wegovy tablets (oral semaglutide co-formulated with an absorption enhancer) making the UK the first country in Europe to licence an oral GLP-1 medicine specifically for weight management. This is a genuinely new option for people who prefer not to inject, or whose circumstances make weekly injections harder to manage.

The Wegovy tablet schedule starts at 1.5 mg once daily, escalating through 4 mg and 9 mg to a 25 mg maintenance dose, with at least a month at each level. It's taken first thing in the morning on an empty stomach, with a small amount of plain water, waiting at least 30 minutes before food, other drinks or any other oral medicines. Because it requires no refrigeration, it can be easier to manage around travel, or around those weeks when a bank holiday catches you out and you need to plan ahead.

Trial evidence from the OASIS 4 phase 3 study (64 weeks, 307 adults with obesity or overweight plus at least one weight-related condition) showed an average weight loss of around 13.6% compared with around 2.4% on placebo. Among participants who adhered fully throughout, the figure reached approximately 17%. Common side effects were gastrointestinal and generally mild to moderate.

The Wegovy tablet is not Rybelsus, Rybelsus uses 3 mg, 7 mg and 14 mg strengths and is licensed for type 2 diabetes. If you're exploring this option, our prescribers can discuss whether the tablet formulation is appropriate during your consultation. You can read more on our Wegovy overview page.

How does semaglutide compare with tirzepatide for weight loss?

For people considering a switch in the broader sense (moving from semaglutide to a different mechanism altogether) it's worth understanding how the main options compare on evidence. The table below summarises the key facts.

NICE recommends tirzepatide under TA1026 and semaglutide injection under TA875. Both appraisals carry eligibility thresholds, and lower BMI thresholds apply for some ethnic backgrounds under UK guidance. Neither figure nor table here should be taken as a recommendation, trial populations, individual health history and tolerability all feed into what is appropriate for you.

If you want to switch to a different semaglutide product or formulation, what happens next?

Any change to your treatment (whether that's moving from the Wegovy injection to the Wegovy tablet, switching from semaglutide to tirzepatide, or transferring your care from another provider) requires a fresh clinical assessment. A prescriber needs to review your current dose, how you're tolerating it, your weight trajectory and your general health before recommending any change. This is true regardless of whether you're switching molecules or just formulations.

At nume, every repeat order and every change is reviewed by a GPhC-registered Independent Prescriber, not processed automatically. If you're currently on Wegovy elsewhere and thinking about switching, our guide to switching your treatment explains what evidence we ask for and how transfer reviews work. You can also read about broader switching scenarios, including moving from liraglutide to semaglutide, or what switching from semaglutide to retatrutide might eventually involve as that pipeline develops.

Which treatment suits you is a clinical decision our prescribers make with you, based on your full picture. If you'd like that conversation, check your eligibility and start a free consultation.